



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

产品名称: [4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide,  
Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[4-(1H-imidazol-1-yl)phenyl]  
产品别名: ISCK03

生物活性:				
Description	ISCK03 is a specific SCF/c-Kit inhibitor.			
In Vitro	Pretreatment of 501mel cells with ISCK03 inhibits SCF-induced c-kit phosphorylation dose dependently. ISCK03 also inhibits p44/42 ERK mitogen-activated protein kinase (MAPK) phosphorylation, which is known to be involved in SCF/c-kit downstream signaling. However ISCK03 does not inhibit hepatocyte growth factor (HGF)-induced phosphorylation of p44/42 ERK proteins[1]. ISCK03, a tyrosine kinase inhibitor specific to KIT, prevents survival of CCDC26-KD cells under low-serum conditions. All treated cells exhibits sensitivity to ISCK03 in a dose-dependent manner. After ISCK03 treatment, the survival of KD cells is suppressed to the same level as that of non-KD cells. Conversely, ISCK03 treatment has limited effects on the growth of control K562 and KD clone 3-4 cells under high-serum concentration conditions[2].			
In Vivo	Oral administration of ISCK03 induces the dose-dependent depigmentation of newly regrown hair, and this is reversed with cessation of ISCK03 treatment. The topical application of ISCK03 promotes the depigmentation of UV-induced hyperpigmented spots. Fontana-Masson staining analysis shows epidermal melanin is diminished in spots treated with ISCK03[1].			
Solvent&Solubility	<b>In Vitro:</b> <b>DMSO : <math>\geq 38</math> mg/mL (106.91 mM)</b> <small>* "<math>\geq</math>" means soluble, but saturation unknown.</small>			
	<b>Preparing Stock Solutions</b>	<b>Solvent Mass Concentration</b>	<b>1 mg</b>	<b>5 mg</b>
		1 mM	2.8133 mL	14.0667 mL
		5 mM	0.5627 mL	2.8133 mL
		10 mM	0.2813 mL	1.4067 mL
	<b>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</b> <b>储备液的保存方式和期限</b> -80°C, 6 months; -20°C, 1 month. -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。 <b>In Vivo:</b> 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶  1.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline) <b>Solubility: <math>\geq 2.5</math> mg/mL (7.03 mM); Clear solution</b> 此方案可获得 $\geq 2.5$ mg/mL (7.03 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 $\mu$ L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 $\mu$ L 20% 的 SBE-β-CD 生理			



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>盐水水溶液中，混合均匀</p> <p>2.请依序添加每种溶剂： 10% DMSO →90% corn oil</p> <p>Solubility: <math>\geq 2.5</math> mg/mL (7.03 mM); Clear solution</p> <p>此方案可获得 <math>\geq 2.5</math> mg/mL (7.03 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 玉米油中，混合均匀。</p>
References	<p>[1]. Na YJ, et al. [4-t-butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs. Biochem Pharmacol. 2007 Sep 1;74(5):780-6.</p> <p>[2]. Hirano T, et al. Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression. Mol Cancer. 2015 Apr 19;14:90. doi: 10.1186/s12943-015-0364-7.</p>
实验参考:	
Cell Assay	<p>To determine any cytotoxic effects of ISCK03 on 501mel cells, MTT assays are performed with various doses of ISCK03 (1, 5, 10 <math>\mu</math>M). 501mel cells are cultured with SCF alone (50 ng/mL) or SCF with ISCK03 for 48 h[1].</p>
Animal Administration	<p>Mice: To induce the hair cycle, depilation of skin on the back of the female C57BL/6 mice is performed. Briefly, the hair is removed from anesthetized mice. The rat antimouse c-kit-neutralizing monoclonal antibody ACK2 is administered intraperitoneally (50 mg) every day. ISCK03 is administered orally once a day. On days 21–28, animals are sacrificed or analyzed for repigmentation of the newly regrown hair shaft. Skin is harvested and fixed in paraffin or frozen for immunohistochemical analyses[1].</p>
Kinase Assay	<p>ATP is dispensed into 384-well plates, chemical compounds (ISCK03: 2.5, 5, 10, 100 <math>\mu</math>M) are added by replicative plate, and recombinant human c-kit protein is added for the kinase reaction. Following a 45-min incubation at 37°C, the development reaction is carried out for 40 min at room temperature. After the reaction is stopped, the coumarin and fluorescein fluorescence-emission signals are detected[1].</p>
References	<p>[1]. Na YJ, et al. [4-t-butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs. Biochem Pharmacol. 2007 Sep 1;74(5):780-6.</p> <p>[2]. Hirano T, et al. Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression. Mol Cancer. 2015 Apr 19;14:90. doi: 10.1186/s12943-015-0364-7.</p>